Takeda Pharmaceutical Company Limited
TAK
$14.16
$0.443.21%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 40.77% | -3,229.30% | -78.22% | 286.26% | -6.18% |
| Total Depreciation and Amortization | 1.98% | -5.63% | -3.27% | 2.38% | -1.31% |
| Total Amortization of Deferred Charges | -- | 20.80% | -- | -- | -- |
| Total Other Non-Cash Items | -65.67% | 264.17% | 314.10% | -727.82% | -164.99% |
| Change in Net Operating Assets | 54.65% | -95.29% | 151.74% | -45.28% | 67.70% |
| Cash from Operations | 36.51% | -22.32% | 153.62% | 37.29% | 62.29% |
| Capital Expenditure | 9.98% | -6.72% | 7.31% | -27.05% | -10.05% |
| Sale of Property, Plant, and Equipment | 76,516.98% | 1,455.56% | -97.10% | -99.66% | -27.97% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 974.83% | -45.49% | -- | 74,856.49% | 596.12% |
| Other Investing Activities | 77.87% | 148.28% | -143.99% | 2.73% | 59.27% |
| Cash from Investing | 77.14% | 68.82% | -48.59% | -20.54% | 48.23% |
| Total Debt Issued | -63.84% | 1,016.33% | -76.47% | -- | 141.73% |
| Total Debt Repaid | -135.22% | -1,948.53% | -429.37% | -247.85% | 29.47% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -2,641.92% | -- | -- | -- | 19.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -13.53% | -3.94% | -1.83% | 1.37% | 6.99% |
| Other Financing Activities | -167.35% | -10.78% | -20.11% | -222.84% | 211.17% |
| Cash from Financing | -173.30% | -404.89% | -549.44% | 23.96% | 582.15% |
| Foreign Exchange rate Adjustments | -115.26% | -189.47% | 810.87% | -1,115.27% | 2.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -110.91% | -162.67% | -1,089.38% | 3,039.15% | 240.79% |